UPCOMING SESSIONS in ET
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next Heather Landau Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
View all sessions

David C. Seldin, MD, PhD (Deceased)

Dr. Seldin was a Director at the Amyloidosis Center and Chief of the Section of Hematology-Oncology at Boston Medical Center. He earned his medical degree from Harvard Medical School and completed his Residency and Internship in Internal Medicine at the Brigham & Women's Hospital, followed by a fellowship in hematology and medical oncology at Brigham & Women's Hospital and Dana Farber Cancer Institute.

Dr. Seldin's research interests included the causes and cures of amyloidosis. He was an active member of the Stem Cell Transplantation Program at Boston Medical Center, and was an investigator on trials using high dose melphalan chemotherapy and autologous stem cell transplantation, and also on trials for novel agents that have the potential for activity against bone marrow plasma cells in AL, including lenalidomide, pomalidomide, bortezomib, MLN9708, and others.

Representative Publications:
First Name
David
Middle Name
C.
Last Name
Seldin
Address
The Amyloidosis Center<br>
Boston University School of Medicine<br>
72 East Concord Street, K-503
Qualification
Type of Expert
Phone
617-358-4750
Country
United States
City
Boston
State
Massachusetts
media
Image
Dr.-Seldin